Ninth WFH Global Forum on Research and Treatment Products for Bleeding Disorders

Access to safe and effective treatment products continues to improve each year due to the tireless advocacy from the global bleeding disorders community.

This strategic priority for the WFH, coupled with the continued support of clinical research which provides evidence to make the case for better care, were integrally linked throughout the WFH Global Forum.

 For the first time, the WFH combined our Global Forum on Treatment Products for Bleeding Disorders with our Global Research Forum, covering the latest developments in both areas. The speakers addressed issues related to the safety and supply of treatment products, as well as discussing and debating critical issues and challenges in the areas of research and clinical trials related to bleeding disorders and their treatment products. More than 170 people from over 30 countries attended the 9th Global Forum, which was held October 22-23, bringing together patient groups, regulators, representatives from industry, not-for-profit fractionators, and researchers as well as doctors who treat people with bleeding disorders.

The first day of the Global Forum focused on safety and supply of treatment products. A session on inhibitors development in hemophilia highlighted the need for continued efforts to develop global surveillance to monitor and understand inhibitors. That session was followed by a detailed look at various supply issues affecting our global community including WFH efforts to increase the world supply of clotting factor concentrates in a sustainable way.


The second day covered research, including novel treatment products that are not clotting factor concentrates and updates on various trials of gene therapy for hemophilia A and B. There was also discussion of how much gene therapy might cost and how it could eventually be rolled out around the world.  The WFH Clinical Research Program was also featured and two presenters gave updates on the work they are doing with the support of WFH Clinical Research Grants.

During the manufacturers session that closed the Global Forum, a record 10 companies presented data on newly licensed or about to be licensed treatment products as well as sharing data from ongoing clinical trials.

The World Federation of Hemophilia wishes to thank the sponsors for supporting the Global Forum: Baxalta, Bayer, Biogen, Canadian Blood Services (CBS), CSL Behring, Hema Quebec, Novo Nordisk, Octapharma, Ministére des Relations Internationales du Quebec (MRI), and SOBI.

The proceedings of the Global Forum will be published later this year. Many presentations from the meeting are already available on our website.